At least 6 hours must separate the two daily doses of irradiation, and the treatment chart must document the times of irradiation. No cytotoxic chemotherapy will be delivered during the period of irradiation, or for 14 days before or after. It is clear that more effective, less toxic therapeutic regimens are needed for patients with metastatic malignant melanoma. He reported that the regimen is well tolerated and preliminary evidence suggests that it may be associated with a high complete response rate. We are pursuing evaluation of this regimen to gain additional information about its safety and efficacy.
Treatment is initiated with temozolomide to release antigens from the melanoma.
It is hypothesized that in this way tumor specific T lymphocytes could be activated. This population is expanded with a low dose of IL-2, administered subcutaneously. Individuals must be at least 18 years of age. Pregnant women are not eligible. Men and women will be required to use an effective form of contraception.